ECTRIMS eLearning

Upper limb function in MS: correlation between instrumental and clinical scale
Author(s): ,
C. Solaro
Affiliations:
Dept. of Rehabilitation, `Mons. L. Novarese` Hospital, Moncrivello (VC)
,
G. Brichetto
Affiliations:
Scientific Research Area, Italian Multiple Sclerosis Foundation (FISM), Genova
,
M. Mueller
Affiliations:
Scientific Research Area, Italian Multiple Sclerosis Foundation (FISM), Genova
,
D. Cattaneo
Affiliations:
Don Gnocchi Foundation, Milano
,
R. Bertoni
Affiliations:
Don Gnocchi Foundation, Milano
,
F. Patti
Affiliations:
MS Center Institute of Neurological Sciences - University of Catania
,
A. Pappalardo
Affiliations:
MS Center Institute of Neurological Sciences, University of Catania, Catania
,
L. Prosperini
Affiliations:
Dept. of Neurology and Psychiatry, Sapienza University, Roma
,
L. Castelli
Affiliations:
Dept. of Neurology and Psychiatry, Sapienza University, Roma
D. Marengo
Affiliations:
Department of Psychology, University of Turin, Torino, Italy
ECTRIMS Learn. Solaro C. 10/10/18; 229241; EP1402
Dr. Claudio Marcello Solaro
Dr. Claudio Marcello Solaro
Contributions
Abstract

Abstract: EP1402

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - Clinical assessment tools

Background: Unlike lower limb dysfunction in MS, there are no validated, self-administered scale and normative data, that assess different dimensions for upper limb functions.
Materials and methods: The main aim of this study is to create a set normative data for both objective and subjective scores; correlate upper limb function scales' scores with subjective scales' score.
183 patients has been enrolled: 125 F/58 M; mean age: 47,18 years; mean EDSS: 4.05; mean disease duration: 14,12 years; 117 RRMS, 47 SPMS, 18 PPMS. They were evaluated using: Hand grip strength; 9 HOLE PEG TEST (HPT); Box and block (BB); MAM-36; DASH.
Results: The results obtained has been (mean): MAM36 (0-100): 72.77; DASH (0-100): 28.52; MFIS (Physical): 16.76; MFIS (Cognitive): 11.61; MFIS (Psychosocial): 3.09; MFIS (Total): 31.46; HAND-GRIP (r): 39.86; HAND-GRIP (l): 36.86; BB(r): 45.75 BB(l): 44.93; 9HPT (right): 27.93; 9HPT (left): 30.88.
Correlation between upper-extremity function tests (* p< .05 ** p< .01) BBleft vs right: 0.88**; 9HPT(Right) vs BB(right): -.47**; 9HPT(Right) vs BB(left): -.38**; 9HPT(left) vs BB(right): -.35**; 9HPT(left) vs BB(left): -.41**; 9HPT(left) vs BB(right): .63**; HAND-GRIP (Right) vs BB(Right): .09; HAND-GRIP (Right) vs BB(left) -.01; HAND-GRIP (Right) vs 9 HPT(Right): -.06; HAND-GRIP (Right) vs 9 HPT(Left): 0.01; HAND-GRIP (Left) vs BB(Right): 0.01; HAND-GRIP (Left) vs BB(Left): .03; 9 HPT(Right) vs HAND-GRIP (Left): .04; HAND-GRIP (Left) vs 9 HPT(Left): -.06; HAND-GRIP (Left) vs HAND-GRIP (Right): .85**.
Discussion and conclusion: In conclusion, we found:
- A strong inter-correlation between right and left hand scores for BB, 9HPT and hand-grip
- A moderate negative correlation between BB and 9HPT, but not a correlation with Hand-grip score.
- A strong negative correlation between MAM-36 and DASH scores: both scores shows moderate-to-strong correlations with MFIS variables
- A moderate correlation between DASH and MAM36 with BB and 9HPT, while correlation with hand-grip was small
Disclosure: Dr. Solaro, Dr. Patti and Dr. Prosperini served on advisory boards of the following companies: Biogen Idec, Merck Serono. He received speaking honoraria from Bayer Schering, Biogen Idec, Merck Serono, Almirall, Teva, Genzyme. He received research grants and support from the Italian MS Society Research Foundation (Fondazione Italiana Sclerosi Multipla)

Abstract: EP1402

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - Clinical assessment tools

Background: Unlike lower limb dysfunction in MS, there are no validated, self-administered scale and normative data, that assess different dimensions for upper limb functions.
Materials and methods: The main aim of this study is to create a set normative data for both objective and subjective scores; correlate upper limb function scales' scores with subjective scales' score.
183 patients has been enrolled: 125 F/58 M; mean age: 47,18 years; mean EDSS: 4.05; mean disease duration: 14,12 years; 117 RRMS, 47 SPMS, 18 PPMS. They were evaluated using: Hand grip strength; 9 HOLE PEG TEST (HPT); Box and block (BB); MAM-36; DASH.
Results: The results obtained has been (mean): MAM36 (0-100): 72.77; DASH (0-100): 28.52; MFIS (Physical): 16.76; MFIS (Cognitive): 11.61; MFIS (Psychosocial): 3.09; MFIS (Total): 31.46; HAND-GRIP (r): 39.86; HAND-GRIP (l): 36.86; BB(r): 45.75 BB(l): 44.93; 9HPT (right): 27.93; 9HPT (left): 30.88.
Correlation between upper-extremity function tests (* p< .05 ** p< .01) BBleft vs right: 0.88**; 9HPT(Right) vs BB(right): -.47**; 9HPT(Right) vs BB(left): -.38**; 9HPT(left) vs BB(right): -.35**; 9HPT(left) vs BB(left): -.41**; 9HPT(left) vs BB(right): .63**; HAND-GRIP (Right) vs BB(Right): .09; HAND-GRIP (Right) vs BB(left) -.01; HAND-GRIP (Right) vs 9 HPT(Right): -.06; HAND-GRIP (Right) vs 9 HPT(Left): 0.01; HAND-GRIP (Left) vs BB(Right): 0.01; HAND-GRIP (Left) vs BB(Left): .03; 9 HPT(Right) vs HAND-GRIP (Left): .04; HAND-GRIP (Left) vs 9 HPT(Left): -.06; HAND-GRIP (Left) vs HAND-GRIP (Right): .85**.
Discussion and conclusion: In conclusion, we found:
- A strong inter-correlation between right and left hand scores for BB, 9HPT and hand-grip
- A moderate negative correlation between BB and 9HPT, but not a correlation with Hand-grip score.
- A strong negative correlation between MAM-36 and DASH scores: both scores shows moderate-to-strong correlations with MFIS variables
- A moderate correlation between DASH and MAM36 with BB and 9HPT, while correlation with hand-grip was small
Disclosure: Dr. Solaro, Dr. Patti and Dr. Prosperini served on advisory boards of the following companies: Biogen Idec, Merck Serono. He received speaking honoraria from Bayer Schering, Biogen Idec, Merck Serono, Almirall, Teva, Genzyme. He received research grants and support from the Italian MS Society Research Foundation (Fondazione Italiana Sclerosi Multipla)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies